Compare TKNO & PAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKNO | PAI |
|---|---|---|
| Founded | 1996 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.9M | 114.9M |
| IPO Year | 2021 | N/A |
| Metric | TKNO | PAI |
|---|---|---|
| Price | $4.76 | $12.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 238.2K | 16.6K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.78% |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $8.27 | N/A |
| Revenue Next Year | $13.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $11.72 |
| 52 Week High | $6.68 | $13.22 |
| Indicator | TKNO | PAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 43.31 |
| Support Level | $4.09 | $12.06 |
| Resistance Level | $4.94 | $12.34 |
| Average True Range (ATR) | 0.47 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 41.95 | 23.02 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. Its primary investment objective is to seek a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. To a lesser extent, the fund also invests in privately placed debt securities and in certain equity securities. Capital appreciation is its secondary investment objective. The fund invests a majority of its net assets in fixed income securities that are rated in the Baa or BBB categories or above at the time of purchase by one or more Nationally Recognized Statistical Rating Organizations (NRSROs) or unrated securities of comparable quality at the time of purchase (as determined by the investment adviser).